- Supported exchanges /
- F /
- 6LP.F
BOLT BIOTHERAP. DL-00001 (6LP F) stock market data APIs
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
BOLT BIOTHERAP. DL-00001 Financial Data Overview
| 0.606 | |
| 0.59 | |
| - | |
| 0.609 | |
| 0.59 | |
| 0.509-1.33 | |
| 22 644 K | |
| 38 265 K | |
| 11 166 K | |
| -0.64 | |
| 0.929 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
BOLT BIOTHERAP. DL-00001 Fundamental Data is available in our Financial Data APIs
- Net Revenue 11 166 K
- EBITDA -72 229 000
- Earnings Per Share -1.61
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get BOLT BIOTHERAP. DL-00001 Earnings via APIs
- Latest Release 2021-06-30
- EPS/Forecast -0.43
Get BOLT BIOTHERAP. DL-00001 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
